批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2020/12/14 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/02/22 |
ORIG-1(原始申请) |
Approval |
|
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:CLOFARABINE 剂型/给药途径:SOLUTION;INTRAVENOUS 规格:20MG/20ML (1MG/ML) 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021673 |
001 |
NDA |
CLOLAR |
CLOFARABINE |
SOLUTION;INTRAVENOUS |
20MG/20ML (1MG/ML) |
Prescription |
Yes |
Yes |
AP |
2004/12/28
|
GENZYME |
204029 |
001 |
ANDA |
CLOFARABINE |
CLOFARABINE |
SOLUTION;INTRAVENOUS |
20MG/20ML (1MG/ML) |
Discontinued |
No |
No |
AP |
2017/05/09
|
ABON PHARMS LLC |
205375 |
001 |
ANDA |
CLOFARABINE |
CLOFARABINE |
SOLUTION;INTRAVENOUS |
20MG/20ML (1MG/ML) |
Prescription |
No |
No |
AP |
2017/11/06
|
DR REDDYS |
208857 |
001 |
ANDA |
CLOFARABINE |
CLOFARABINE |
SOLUTION;INTRAVENOUS |
20MG/20ML (1MG/ML) |
Prescription |
No |
No |
AP |
2017/11/06
|
AMNEAL |
208860 |
001 |
ANDA |
CLOFARABINE |
CLOFARABINE |
SOLUTION;INTRAVENOUS |
20MG/20ML (1MG/ML) |
Prescription |
No |
No |
AP |
2017/11/06
|
MYLAN LABS LTD |
209775 |
001 |
ANDA |
CLOFARABINE |
CLOFARABINE |
SOLUTION;INTRAVENOUS |
20MG/20ML (1MG/ML) |
Prescription |
No |
No |
AP |
2017/12/06
|
MSN |
207831 |
001 |
ANDA |
CLOFARABINE |
CLOFARABINE |
SOLUTION;INTRAVENOUS |
20MG/20ML (1MG/ML) |
Prescription |
No |
No |
AP |
2018/10/31
|
GLAND PHARMA LTD |
212034 |
001 |
ANDA |
CLOFARABINE |
CLOFARABINE |
SOLUTION;INTRAVENOUS |
20MG/20ML (1MG/ML) |
Prescription |
No |
No |
AP |
2019/02/22
|
ACCORD HLTHCARE |
213461 |
001 |
ANDA |
CLOFARABINE |
CLOFARABINE |
SOLUTION;INTRAVENOUS |
20MG/20ML (1MG/ML) |
Prescription |
No |
No |
AP |
2020/10/23
|
MEITHEAL |
212457 |
001 |
ANDA |
CLOFARABINE |
CLOFARABINE |
SOLUTION;INTRAVENOUS |
20MG/20ML (1MG/ML) |
Discontinued |
No |
No |
AP |
2022/10/03
|
EUGIA PHARMA |